Effect of Toll-like Receptor-3 Antagonist on Viral Asthma Exacerbations Via a TLR3/dsRNA Complex Pathway
- Authors: Arora S.1, Singh K.2, Saha S.2, Kumar S.2, Khalid M.3, Akram W.4, Alam S.1, Sahu K.K.5, Agrawal M.6, Chaudhary H.6
-
Affiliations:
- Department of Pharmacology, R.V Northland Institute of Pharmacy, U.P., 201301, India
- Department of Pharmacy, Rajiv Academy for Pharmacy, Mathura, India
- Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj, 11942, Saudi Arabia
- Department of Pharmacology, SPER, Jamia Hamdard University, New Delhi, 110062, India
- Institute of Pharmaceutical Research, GLA University, Mathura, India
- School of Medical and Allied Sciences, K.R. Mangalam University, Gurugram, India
- Issue: Vol 22, No 3 (2024)
- Section: Medicine
- URL: https://rjeid.com/2211-3525/article/view/642315
- DOI: https://doi.org/10.2174/0122113525282849231228125935
- ID: 642315
Cite item
Full Text
Abstract
Background:The Toll-like receptor-3 (TLR3) ligand Poly(I:C) has been shown to induce a viral aggravation of severe asthma by identifying double-stranded RNA (dsRNA). This study aimed to evaluate the therapeutic role of the TLR3/dsRNA complex inhibitor-calbiochem compound in the treatment of Poly(I:C)-induced viral asthma exacerbations through the ovalbu-min-induced asthma model in Swiss albino mice.
Methods:Poly(I:C) and Ovalbumin drugs were injected in mice to sensitize (i.p. on 0, 7, and 14th day) and challenge (i.n. on the 21st and 22nd days). In contrast, the treatment drug TLR3/dsRNA complex inhibitor-calbiochem was given on the 21st and 22nd days intraperitoneally within the study period. In-vivo measurements were carried out in BALF and serum for pro-inflammatory cytokines, inflammatory leukocyte counts, lactate dehydrogenase (LDH) and nitrite levels, lungs/body weight index, and lung tissue histopathology using H and E staining in mice airways.
Results:High levels of cytokines (NF-κB, IL-1β, IL-5, RANTES, MIP-2, and MCP-1) are seen in groups exposed to OVA and Poly (I:C). Further, inflammatory leukocyte cell counts, lung-body weight (LW/BW) index, airway hyperresponsiveness (AHR), and lung tissue damage sug-gest exacerbations in mice airways. On the other hand, TLR3/dsRNA complex inhibitor-calbio-chem and dexamethasone significantly reversed these changes toward normal levels.
Conclusions:These results suggest that the novel compound TLR3/dsRNA complex inhibitor-calbiochem has a better therapeutic role than dexamethasone for managing inflammatory char-acteristics in asthmatic mice lungs and is a potent target for viral asthma exacerbations
Keywords
About the authors
Swamita Arora
Department of Pharmacology, R.V Northland Institute of Pharmacy, U.P., 201301, India
Email: info@benthamscience.net
Kuldeep Singh
Departmentof Pharmacy, Rajiv Academy for Pharmacy, Mathura, India
Email: info@benthamscience.net
Sunam Saha
Departmentof Pharmacy, Rajiv Academy for Pharmacy, Mathura, India
Email: info@benthamscience.net
Shivendra Kumar
Departmentof Pharmacy, Rajiv Academy for Pharmacy, Mathura, India
Author for correspondence.
Email: info@benthamscience.net
Mohammad Khalid
Department ofPharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj, 11942, Saudi Arabia
Email: info@benthamscience.net
Wasim Akram
Department of Pharmacology, SPER, Jamia Hamdard University, New Delhi, 110062, India
Email: info@benthamscience.net
Sanjar Alam
Department of Pharmacology, R.V Northland Institute of Pharmacy, U.P., 201301, India
Email: info@benthamscience.net
Kantrol Kumar Sahu
Institute of Pharmaceutical Research, GLA University, Mathura,India
Email: info@benthamscience.net
Mohit Agrawal
School of Medical and AlliedSciences, K.R. Mangalam University, Gurugram, India
Email: info@benthamscience.net
Hema Chaudhary
School of Medical and AlliedSciences, K.R. Mangalam University, Gurugram, India
Email: info@benthamscience.net
Supplementary files
